原发性纵隔大B细胞淋巴瘤的诊治现状

程瑶; 施菊妹

doi:10.13201/j.issn.1004-2806.2023.03.014

原发性纵隔大B细胞淋巴瘤的诊治现状

程瑶¹,
施菊妹^2, ,

- 1.
  同济大学附属第十人民医院血液科(上海，200072)
- 2.
  同济大学附属东方医院血液科

详细信息

通讯作者: 施菊妹，E-mail：shijumei@tongji.edu.cn

中图分类号: R733.4

收稿日期: 2022-05-11

刊出日期: 2023-03-01

The diagnosis and treatment of primary mediastinal large B-cell lymphoma

CHENG Yao¹,
SHI Jumei^2, ,

- 1.
  Department of Hematology, the 10th People's Hospital Affiliated to Tongji University, Shanghai, 200072, China
- 2.
  Department of Hematology, Shanghai East Hospital, Tongji University School of Medicine

More Information

Corresponding author: SHI Jumei, E-mail: shijumei@tongji.edu.cn

Received Date: 11 May 2022

Publish Date: 01 March 2023

摘要

摘要: 原发性纵隔大B细胞淋巴瘤是一种较为少见的血液系统恶性肿瘤，其诊断与治疗目前尚无统一的指南可供参考。近几年随着研究者更多的关注此疾病，其在诊断及治疗方面存在的困难及问题被一一指出；目前普遍认可的诊断方法为结合临床表现、形态学、免疫表型及影像学综合诊断；一线治疗多以免疫化疗方案联合/不联合巩固性放疗为首选，难治/复发性原发性纵隔大B细胞淋巴瘤的治疗则以靶向治疗和造血干细胞移植多见；但仍存在较多争议及问题有待解决。了解原发性纵隔大B细胞淋巴瘤的诊断及治疗对临床工作中减少漏诊及误诊具有重要意义。
- 原发性纵隔大B细胞淋巴瘤 /
- 诊断 /
- 治疗
Abstract: Primary mediastinal large B cell lymphoma is a relatively rare hematological malignancy, and there are no unified guidelines for its diagnosis and treatment. In recent years, as researchers pay more attention to this disease, the difficulties and problems existing in the diagnosis and treatment have been pointed out one by one. At present, the widely recognized diagnostic method is combining clinical manifestations, morphology, inventing and imaging comprehensive diagnosis. Immunochemotherapy combined with/without consolidative radiation is the first choice for the first-line treatment, while targeted therapy and hematopoietic stem cell transplantation are the most common treatments for relapsed/refractory primary mediastinal large B-cell lymphoma, but there are still many controversies and problems to be resolved. Understanding the diagnosis and treatment of primary mediastinal large B-cell lymphoma is of great significance to reduce missed diagnosis and misdiagnosis in clinical work.
- primary mediastinal large B-cell lymphoma /
- diagnosis /
- therapy

HTML全文

参考文献(27)

[1]	Smith J, Kumar A, Stanton NA, et al. Concurrent application of blinatumomab and haploidentical donor leukocyte infusions for refractory primary mediastinal large B-cell lymphoma[J]. Ther Adv Hematol, 2021, 12: 2040620721994348.
[2]	de-la-Fuente C, Nuñez F, Cortés-Romera M, et al. Pembrolizumab for refractory primary mediastinal B-cell lymphoma with central nervous system involvement[J]. Hematol Oncol, 2021, 39(3): 419-422. doi: 10.1002/hon.2836
[3]	Yu Y, Dong X, Tu M, et al. Primary mediastinal large B cell lymphoma[J]. Thorac Cancer, 2021, 12(21): 2831-2837. doi: 10.1111/1759-7714.14155
[4]	Svoboda J, Bair SM, Landsburg DJ, et al. Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas[J]. Haematologica, 2021, 106(6): 1705-1713.
[5]	Liu Y, Jiang J, Liu L, et al. Prognostic significance of clinical characteristics and 18Fluorodeoxyglucose-positron emission tomography/computed tomography quantitative parameters in patients with primary mediastinal B-cell lymphoma[J]. J Int Med Res, 2022, 50(1): 3000605211063027.
[6]	Ondrejka SL, Ott G. How I Diagnose Primary Mediastinal(Thymic)Large B-Cell Lymphoma[J]. Am J Clin Pathol, 2021, 156(4): 497-512. doi: 10.1093/ajcp/aqab122
[7]	Jacquier A, Syrykh C, Bedgedjian I, et al. Immunohistochemistry with anti-MAL antibody and RNAscope with MAL probes are complementary techniques for diagnosis of primary mediastinal large B-cell lymphoma[J]. J Clin Pathol, 2020, 74(6): 396-399.
[8]	Pfau D, Smith DA, Beck R, et al. Primary Mediastinal Large B-Cell Lymphoma: A Review for Radiologists[J]. AJR Am J Roentgenol, 2019, 213(5): W194-W210. doi: 10.2214/AJR.19.21225
[9]	Jiang Y, Mo W, Miao Y, et al. Primary mediastinal large B cell lymphoma with coexisting aberrations of C-MYC and BCL-2: a case report and literature review[J]. Med Mol Morphol, 2020, 53(2): 124-129. doi: 10.1007/s00795-019-00237-2
[10]	Wästerlid T, Hasselblom S, Joelsson J, et al. Real-world data on treatment and outcomes of patients with primary mediastinal large B-cell lymphoma: a Swedish lymphoma register study[J]. Blood Cancer J, 2021, 11(5): 100. doi: 10.1038/s41408-021-00491-7
[11]	Venkitakrishnan R, Paul M, Sleeba T, et al. Expecting the unexpected-Primary mediastinal large B cell lymphoma presenting as huge lung parenchymal mass[J]. Respir Med Case Rep, 2021, 32: 101370.
[12]	Besteiro B, Teixeira C, Gullo I, et al. Superior vena cava syndrome caused by mediastinal lymphoma: A rare clinical case[J]. Radiol Case Rep, 2021, 16(4): 929-933. doi: 10.1016/j.radcr.2021.01.063
[13]	Yang X, Laliberté F, Germain G, et al. Treatment patterns, healthcare resource utilization, and costs of patients diagnosed with primary mediastinal B-cell lymphoma in the United States[J]. J Med Econ, 2021, 24(1): 469-478. doi: 10.1080/13696998.2021.1908001
[14]	Gentille C, Anand K, Dalwadi S, et al. Radiation therapy in primary mediastinal large B-cell lymphoma treated with DA-R-EPOCH[J]. Clin Case Rep, 2020, 8(7): 1153-1155. doi: 10.1002/ccr3.2853
[15]	Jain H, Kapoor A, Sengar M, et al. Outcomes of Patients with Primary Mediastinal B-Cell Lymphoma Treated with Dose Adjusted R-EPOCH Regimen: A Single Centre Experience[J]. Indian J Hematol Blood Transfus, 2021, 37(3): 379-385. doi: 10.1007/s12288-020-01372-y
[16]	Vassilakopoulos TP, Michail M, Papageorgiou S, et al. Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP[J]. Oncologist, 2021, 26(7): 597-609. doi: 10.1002/onco.13789
[17]	Camus V, Bigenwald C, Ribrag V, et al. Pembrolizumab in the treatment of refractory primary mediastinal large B-cell lymphoma: safety and efficacy[J]. Expert Rev Anticancer Ther, 2021, 21(9): 941-956. doi: 10.1080/14737140.2021.1953986
[18]	Hayden AR, Tonseth P, Lee DG, et al. Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach[J]. Blood, 2020, 136(24): 2803-2811. doi: 10.1182/blood.2019004296
[19]	Camus V, Rossi C, Sesques P, et al. Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study[J]. Blood Adv, 2021, 5(19): 3862-3872. doi: 10.1182/bloodadvances.2021004778
[20]	Chen H, Pan T, He Y, et al. Primary Mediastinal B-Cell Lymphoma: Novel Precision Therapies and Future Directions[J]. Front Oncol, 2021, 11: 654854. doi: 10.3389/fonc.2021.654854
[21]	蒋瑛, 刘慧霞, 朱骏, 等. 自体移植联合抗CD19 CAR-T治疗难治性弥漫大B细胞淋巴瘤的临床观察研究[J]. 临床血液学杂志, 2021, 34(11): 771-775. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXZ202111005.htm
[22]	Kanwal B. Untangling Triple-Negative Breast Cancer Molecular Peculiarity and Chemo-Resistance: Trailing Towards Marker-Based Targeted Therapies[J]. Cureus, 2021, 13(7): e16636.
[23]	Dimou M, Bitsani A, Bethge W, et al. Pembrolizumab-induced Remission After Failure of Axicabtagene Ciloleucel: Case Report and Literature Review[J]. In Vivo, 2021, 35(6): 3401-3406. doi: 10.21873/invivo.12639
[24]	Armand P, Rodig S, Melnichenko V, et al. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma[J]. J Clin Oncol, 2019, 37(34): 3291-3299. doi: 10.1200/JCO.19.01389
[25]	Huang S, Nong L, Liang L, et al. Comparison of PD-L1 detection assays and corresponding significance in evaluation of diffuse large B-cell lymphoma[J]. Cancer Med, 2019, 8(8): 3831-3845. doi: 10.1002/cam4.2316
[26]	Gerhardt K, Jentzsch M, Georgi T, et al. Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases[J]. Front Oncol, 2021, 11: 737645. doi: 10.3389/fonc.2021.737645
[27]	Fujimoto A, Anzai T, Fukuda T, et al. Impact of event-free survival status after stem cell transplantation on subsequent survival of patients with lymphoma[J]. Blood Adv, 2021, 5(5): 1412-1424.